Alzheimer disease and associated disorders最新文献

{"title":"Correlation of Depression and Anxiety Responses on the Mild Behavioral Impairment Checklist With the Cornell Scale for Depression in Dementia and Abbreviated Version of the Penn State Worry Questionnaire.","authors":"Aditya Aundhakar, Fahad Rajput, Aravind Ganesh, Zahinoor Ismail, Eric E Smith","doi":"10.1097/WAD.0000000000000675","DOIUrl":"10.1097/WAD.0000000000000675","url":null,"abstract":"<p><strong>Introduction: </strong>Cognitive disorders are often accompanied by depression and anxiety. The Mild Behavioral Impairment Checklist (MBI-C) was developed to capture neuropsychiatric symptoms that predict risk for dementia and includes questions on mood, but has not been validated for identifying significant depression or anxiety symptoms. Our objective was to determine whether MBI-C mood domain scores predict responses on 2 previously validated scales: the Cornell Scale for Depression in Dementia (CSDD) and the Penn State Worry Questionnaire-Abbreviated version (PSWQ-A) scales.</p><p><strong>Methods: </strong>We performed a cross-sectional analysis of consenting patients from a memory clinic who completed the MBI-C along with the CSDD (n=80) or PSWQ-A (n=92).</p><p><strong>Results: </strong>MBI-C mood scores and the MBI-C depression subscore were moderately to strongly correlated with the CSDD (r=0.72) and the PSWQ-A (r=0.66). An MBI-C mood score of ≥5 or anxiety or depression subscore ≥2 predicted clinically relevant depressive and anxiety symptoms on the CSDD and PSWQ, respectively, with AUCs between 0.80 and 0.85.</p><p><strong>Conclusions: </strong>This study supports the MBI-C mood score as a valid tool for screening for mood-related neuropsychiatric symptoms in individuals with cognitive impairment.</p>","PeriodicalId":520551,"journal":{"name":"Alzheimer disease and associated disorders","volume":"39 2","pages":"93-98"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment: Metformin in Alzheimer Dementia Prevention (MAP).","authors":"José A Luchsinger, Davangere Devanand, Terry E Goldberg, Sam Cammack, Gabriela Hernández-Santiago, Kenichi Oishi, William Jagust, Suzanne Baker, Susan Landau, Gayane Yenokyan, Joshua Betz, Stephanie Mayers, Lindsay M Eyzaguirre, Daniel Hanley","doi":"10.1097/WAD.0000000000000677","DOIUrl":"10.1097/WAD.0000000000000677","url":null,"abstract":"<p><strong>Background: </strong>Metformin has been suggested as a possible strategy for the prevention of Alzheimer disease (AD) and AD related dementias. An early phase II clinical trial of short acting metformin versus placebo showed preliminary evidence of efficacy and safety in slowing cognitive decline among persons with amnestic mild cognitive impairment (aMCI) without diabetes.</p><p><strong>Objective: </strong>To conduct a phase II/III randomized clinical of extended-release metformin versus placebo in participants with aMCI without diabetes.</p><p><strong>Methods: </strong>Ratio of 1:1 randomized placebo-controlled trial of extended-release metformin in 326 persons with aMCI without diabetes, aged 55 to 90 years, lasting 18 months, with 4 visits every 6 months including baseline. The primary outcome is changes in total recall in the Free and Cued Selective Reminding Test. Secondary outcomes include (1) changes in global cognitive performance, measured with the Alzheimer Disease Cooperative Study Preclinical Alzheimer Cognitive Composite (ADCS-PACC); (2) changes in neurodegeneration, ascertained as cortical thickness in areas affected by AD on brain MRI; (3) changes in cerebrovascular disease, ascertained as white matter hyperintensities (WMH) volume on brain MRI; (4) changes in whole brain amyloid ß (Aß) SUVR and in incident amyloid positivity; (5) changes in tau SUVR in a composite brain region comprising medial and inferolateral temporal cortex; (6) changes in plasma AD biomarkers.</p><p><strong>Conclusion: </strong>Observational studies and pilot trials suggest that metformin may help prevent cognitive decline in neurodegenerative disorders. This clinical trial aims to assess metformin's potential in preventing cognitive decline in at-risk individuals and its impact on biomarkers indicative of disease modification.</p>","PeriodicalId":520551,"journal":{"name":"Alzheimer disease and associated disorders","volume":"39 2","pages":"123-133"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebrospinal Fluid Biomarkers and Cognition in Alzheimer Disease and Frontotemporal Dementia in a Memory Clinic Setting.","authors":"Salih Cayir, Faranak Ebrahimian Sadabad, Adam P Mecca, David Matuskey, Arman Fesharaki-Zadeh","doi":"10.1097/WAD.0000000000000656","DOIUrl":"10.1097/WAD.0000000000000656","url":null,"abstract":"<p><strong>Objective: </strong>Currently available literature on the relationships between cerebrospinal fluid (CSF) biomarkers and cognitive performance in frontotemporal dementia (FTD) is very limited and inconclusive. In this study, we investigated the association of cognitive symptoms, as measured with Montreal Cognitive Assessment (MoCA), with CSF levels of total tau (t-tau), phosphorylated tau at threonine 181 (p-tau181), and amyloid β 1-42 (Aβ1-42) in a group of patients with probable FTD and Alzheimer disease (AD).</p><p><strong>Methods: </strong>We conducted a retrospective cohort study with participants selected from the electronic records of patients seen at Yale New Haven Hospital's Memory Clinic, CT. A total of 61 patients, 28 with FTD (mean age=64.1) and 33 with AD (mean age=66.8), with available CSF results and cognitive test scores in their chart were included in analyses.</p><p><strong>Results: </strong>T-tau levels negatively and significantly correlated with total MoCA scores as well as the different MoCA index scores in patients with FTD (r=-0.47, P=0.04). There were no significant associations between MoCA scores and p-tau181 levels in patients with FTD (r=-0.22, P=0.25). Patients with AD exhibited significant correlations between MoCA scores and both t-tau (r=-0.54, P<0.01) and p-tau (r=-0.55, P<0.01) levels. Also, Aβ1-42 levels were not significantly correlated with MoCA scores in either of the FTD and AD groups.</p><p><strong>Conclusion: </strong>CSF concentrations of t-tau are inversely correlated to cognitive performance in patients with FTD and both t-tau and p-tau181 in AD. This study provides valuable insights into the relationship between clinical cognitive performance and tau-related pathology in FTD in comparison with AD.</p>","PeriodicalId":520551,"journal":{"name":"Alzheimer disease and associated disorders","volume":"39 1","pages":"22-27"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Prevalence of Legal Protection Among the Elderly With Neurocognitive Disorders in France.","authors":"Pierre Koskas, Cornélia P A Hounkonnou, Camille Couffignal","doi":"10.1097/WAD.0000000000000653","DOIUrl":"10.1097/WAD.0000000000000653","url":null,"abstract":"<p><p>The prevalence of major neurocognitive disorders (MNCD) increases to 30% after 80 years of age. Vulnerability often goes unnoticed for a long time, and patients are seldom subject to legal protection (LP), creating an ethical and legal dilemma. The French National Alzheimer's Database (BNA) is a national network set up in 2005 to collect data on neurocognitive disorders from all memory clinics in France. Data extraction from the BNA in 2022 produced a sample of 1,187,199 patients. We retained 795,953 patients, with a mean age of 78 years, and approximately two-thirds of the patients were women. We excluded patients with no medical assessment (n=135,810), without MNCD (n=237,209), birth year ≥1981 (n=18,189), and consultation date <2005 (n=38). A total of 32,593 patients (4.09%) have had LP during the 15-year study period. They have lower MMSE scores than others (17.9±6.6 vs. 20.6±6.5 P<0.01), more likely to live alone (45.25% vs. 36,1% P<0.01) or at nursing home (22.83% vs. 8.35% P<0.01). The low prevalence of LP among persons with MNCD emphasizes the potential vulnerability and legal risk of this group.</p>","PeriodicalId":520551,"journal":{"name":"Alzheimer disease and associated disorders","volume":"39 1","pages":"64-66"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship Between Decision-making Capacity and the Domains of Awareness in Alzheimer Disease.","authors":"Natalie A P de Souza,&nbsp;Felipe de Oliveira,&nbsp;Raquel L S de Carvalho,&nbsp;Marcia C N Dourado","doi":"10.1097/WAD.0000000000000484","DOIUrl":"https://doi.org/10.1097/WAD.0000000000000484","url":null,"abstract":"<p><p>People with Alzheimer dementia (PwAD) who are aware of their overall cognitive function and diagnosis are more likely to be judged competent in decision-making capacity. Therefore, we aimed to investigate the relationship between decision-making capacity and the different domains of awareness and the relationship between decision-making capacity and the cognitive and clinical impairment of the PwAD. Using a cross-sectional design, we included 121 PwAD and their caregivers. Awareness was assessed across domains, including cognitive functioning and health condition, functional activity impairments, emotional state, social functioning, and interpersonal relationships. The MacArthur Competence Assessment Tool for Treatment was adopted to gather information about decision-making abilities. We found that decision-making capacity is related to the cognitive and functional domains of awareness and relatively independent of the emotional functioning and the relationship domains. Our finding highlighted that PwAD who are unaware of the disease or the cognitive and functional impairments might be unlikely to appreciate the personal benefits of a proposed health treatment or to understand and judge the personal consequences of a decision accurately.</p>","PeriodicalId":520551,"journal":{"name":"Alzheimer disease and associated disorders","volume":" ","pages":"58-63"},"PeriodicalIF":2.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39867571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Variants and Haplotypes of TOMM40, APOE, and APOC1 are Related to the Age of Onset of Late-onset Alzheimer Disease in a Colombian Population.","authors":"Jenny Ortega-Rojas,&nbsp;Carlos E Arboleda-Bustos,&nbsp;Esneyder Guerrero,&nbsp;Juan Neira,&nbsp;Humberto Arboleda","doi":"10.1097/WAD.0000000000000477","DOIUrl":"https://doi.org/10.1097/WAD.0000000000000477","url":null,"abstract":"<p><strong>Background: </strong>The Apolipoprotein E (APOE) gene is the main risk factor for late-onset Alzheimer disease (LOAD). Genetic variants and haplotypes in regions near the APOE locus may be associated with LOAD in the Colombian population.</p><p><strong>Objective: </strong>We evaluated frequencies and risk of genetic variants and haplotypes in APOE, TOMM40, and APOC1 promoters, also in putative regulatory enhancer elements (TOMM40 IVS2-4 and TOMM40 IVS6), and in cis-regulatory elements (ME1 and BCR).</p><p><strong>Materials and methods: </strong>Our case-control association study was carried out in 50 patients with LOAD and 50 controls. We determined frequencies and odd ratios for genetic variants and haplotypes.</p><p><strong>Results: </strong>We found a significant association between LOAD and genetic variants at the TOMM40 promoter, at TOMM40 IVS2-4 and TOMM40 IVS6 regulatory enhancer elements, and at the APOC1 promoter. Particularly, variants of Poly-T and APOC1 promoter could anticipate the age of onset of LOAD in our population. We identified three risk haplotypes in TOMM40 (ACGGAG, ACGGGG, and ATAGGC) related to LOAD's age of onset. We also found other risk or protection haplotypes at the TOMM40 and APOE promoters, at TOMM40 IVS2-4, TOMM40 IVS6 regulatory enhancer elements, and at ME1.</p><p><strong>Conclusion: </strong>Genetic variants and haplotypes near the APOE locus are related to LOAD risk and accelerated onset of LOAD in the Colombian population.</p>","PeriodicalId":520551,"journal":{"name":"Alzheimer disease and associated disorders","volume":" ","pages":"29-35"},"PeriodicalIF":2.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39911197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Amyloid PET Disclosure on Quality of Life in Patients With Young Onset Dementia.","authors":"Daniël M van der Doelen,&nbsp;Ron L H Handels,&nbsp;Marissa D Zwan,&nbsp;Sander M J van Kuijk,&nbsp;Wiesje Pelkmans,&nbsp;Femke H Bouwman,&nbsp;Philip Scheltens,&nbsp;Carmen D Dirksen,&nbsp;Frans R J Verhey","doi":"10.1097/WAD.0000000000000470","DOIUrl":"https://doi.org/10.1097/WAD.0000000000000470","url":null,"abstract":"<p><strong>Introduction: </strong>The impact of amyloid positron emission tomography (PET) imaging on patient health outcomes for individuals with dementia is unknown. In the present study, we explored the association between diagnostic outcome and clinician's level of certainty with quality of life (QoL) after [18F]flutemetamol PET results were disclosed in young onset dementia patients in a memory clinic cohort.</p><p><strong>Methods: </strong>In 154 patients suspected of dementia, QoL was measured before and after [18F]flutemetamol PET results were disclosed. Multiple regression analyses were conducted with (changed) general and disease-specific QoL measures as dependent factors [QoL-Alzheimer disease (AD) and EQ-5D Dutch tariff] and etiological diagnosis and clinician's certainty as independent factors.</p><p><strong>Results: </strong>(Change in) diagnosis of AD was associated to QOL in 2 of the 4 analyses (utility-based QoL β=0.15, P=0.010; disease-specific QoL β=2.0, P=0.037). Diagnostic certainty was associated to QOL in 1 of the 4 analyses (generic QoL β=0.002, P=0.028).</p><p><strong>Discussion: </strong>The diverse results in this explorative analysis do not reflect a univocal association between diagnosis, certainty, and QoL. Nevertheless, this result could be interpreted as a possible potential for advanced diagnostic technologies for AD, which requires confirmation in future research.</p>","PeriodicalId":520551,"journal":{"name":"Alzheimer disease and associated disorders","volume":" ","pages":"1-6"},"PeriodicalIF":2.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39949554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Moderating Role of Pain Self-efficacy in the Relationships Among Caregiver Burden and Care Recipient Pain and Neuropsychiatric Symptoms in a Sample of Persons With Dementia.","authors":"Karlee S Patrick,&nbsp;John T Martin,&nbsp;Kimberly R Chapman,&nbsp;Jason R Anderson,&nbsp;Mary B Spitznagel","doi":"10.1097/WAD.0000000000000451","DOIUrl":"https://doi.org/10.1097/WAD.0000000000000451","url":null,"abstract":"<p><p>Past research suggests relationships among dementia caregiver burden and care recipient pain and neuropsychiatric symptoms, but no prior work has examined the influence of pain self-efficacy on these associations. A sample of 502 dementia caregivers completed an online protocol assessing caregiver burden and care recipient neuropsychiatric symptoms, presence of pain, and pain self-efficacy in this cross-sectional, observational study. The indirect effect of neuropsychiatric symptoms on the relationship between pain and caregiver burden was significant. Pain self-efficacy significantly moderated the effect of pain on neuropsychiatric symptoms (P=0.04) and the direct association between pain and caregiver burden (P=0.004), but did not moderate the indirect effect. Future research should explore how pain influences neuropsychiatric symptoms, and whether improvement in pain self-efficacy in dementia care recipients attenuates the influence of pain on neuropsychiatric symptoms and caregiver burden in other samples.</p>","PeriodicalId":520551,"journal":{"name":"Alzheimer disease and associated disorders","volume":" ","pages":"85-88"},"PeriodicalIF":2.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38895712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Mineral Density Measurements and Association With Brain Structure and Cognitive Function: The Framingham Offspring Cohort: Erratum.","authors":"","doi":"10.1097/WAD.0000000000000499","DOIUrl":"https://doi.org/10.1097/WAD.0000000000000499","url":null,"abstract":"","PeriodicalId":520551,"journal":{"name":"Alzheimer disease and associated disorders","volume":" ","pages":"95"},"PeriodicalIF":2.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39949555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Short Version of the 10/66 Dementia Diagnosis in Urdu in Karachi, Pakistan.","authors":"Qurat Ul Ain Khan,&nbsp;Martin J Prince","doi":"10.1097/WAD.0000000000000467","DOIUrl":"https://doi.org/10.1097/WAD.0000000000000467","url":null,"abstract":"<p><p>The standard 10/66 battery has been translated and validated in Pakistan; however, it takes long to administer it with specialized training for the staff. This study was performed to validate a shorter version of the 10/66. The data for validation of the short version was extracted from the full version study. Ethical approval was taken from the Institutional Review Board of the Aga Khan University. The study was funded by the Aga Khan University, University Research Council Grant. The total number of participants was 257, equally divided between people with dementia and normal cognition. The sensitivity of the short version was 95.7% and 80.5%; specificity was 83.5% and 90.7%; κ was 0.751 and 0.712; and the area under the curve was 0.89 and 0.85 against the standard 10/66 diagnosis and clinician diagnosis, respectively. The short version of 10/66 battery is a valid instrument for diagnosing dementia in the Urdu-speaking Pakistani population.</p>","PeriodicalId":520551,"journal":{"name":"Alzheimer disease and associated disorders","volume":" ","pages":"89-91"},"PeriodicalIF":2.1,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39223287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}